MARKET

SESN

SESN

Sesen Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.130
-0.310
-12.70%
Opening 11:21 03/05 EST
OPEN
2.410
PREV CLOSE
2.440
HIGH
2.420
LOW
2.120
VOLUME
2.69M
TURNOVER
--
52 WEEK HIGH
3.540
52 WEEK LOW
0.3700
MARKET CAP
336.93M
P/E (TTM)
-5.5454
1D
5D
1M
3M
1Y
5Y
Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Companys Lead Product Candidate Vicineum
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conference call with Dr. Neal Shore, medical director of the Car...
Business Wire · 3d ago
DJ Sesen Bio Shares Extend Gains After FDA Accepts Vicineum Application
Dow Jones · 02/17 20:41
Sesen Bio amends capital raise to include additional $34.5M
Sesen Bio ([[SESN]] +4.8%) has entered into an amendment for its Open Market Sale Agreement, to issue and sell, through Jefferies, up to an additional $34.5M of shares with a
Seekingalpha · 02/17 17:10
DJ Sesen Bio Price Target Raised to $7.00/Share From $5.00 by Canaccord Genuity
Dow Jones · 02/17 15:28
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16)
Benzinga · 02/17 12:26
DJ Sesen Bio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/17 12:03
DJ Sesen Bio Price Target Raised to $8.00/Share From $2.25 by HC Wainwright & Co.
Dow Jones · 02/17 12:03
--Analyst Actions: Jefferies Adjusts Price Target for Sesen Bio to $6 From $3, Maintains Buy Rating
MT Newswires · 02/17 11:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SESN. Analyze the recent business situations of Sesen Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SESN stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 78
Institutional Holdings: 38.57M
% Owned: 24.39%
Shares Outstanding: 158.18M
TypeInstitutionsShares
Increased
16
3.98M
New
16
1.32M
Decreased
12
701.17K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.69%
Pharmaceuticals & Medical Research
-1.52%
Key Executives
Chairman/Independent Director
Jay Duker
President/Chief Executive Officer/Director
Thomas Cannell
Chief Financial Officer/Treasurer
Monica Forbes
Chief Technology Officer
Glen MacDonald
General Counsel/Secretary
Mark Sullivan
Independent Director
Carrie Bourdow
Independent Director
Jane Henderson
Independent Director
Jason Keyes
Independent Director
Daniel Lynch
No Data
About SESN
Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.

Webull offers kinds of Sesen Bio Inc stock information, including NASDAQ:SESN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SESN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SESN stock methods without spending real money on the virtual paper trading platform.